1. Perra D, Alba MA, Callejas JL, et al. Adalimumab for the treatment of Behçet's disease: experience in 19 patients. Rheumatology (Oxford). 2012; 51:1825–1831. PMID:
22723596.
2. Ketch LL, Buerk CA, Liechty D. Surgical implications of Behçet's disease. Arch Surg. 1980; 115:759–760. PMID:
6966918.
3. Ogawa H, Kuroda T, Inada M, et al. Intestinal Behçet's disease associated with myelodysplastic syndrome with chromosomal trisomy 8-a report of two cases and a review of the literature. Hepatogastroenterology. 2001; 48:416–420. PMID:
11379321.
4. Kimura S, Kuroda J, Akaogi T, Hayashi H, Kobayashi Y, Kondo M. Trisomy 8 involved in myelodysplastic syndromes as a risk factor for intestinal ulcers and thrombosis-Behcet's syndrome. Leuk Lymphoma. 2001; 42:115–121. PMID:
11699198.
5. Kawabata H, Sawaki T, Kawanami T, et al. Myelodysplastic syndrome complicated with inflammatory intestinal ulcers: significance of trisomy 8. Intern Med. 2006; 45:1309–1314. PMID:
17170506.
6. Mundle SD, Ali A, Cartlidge JD, et al. Evidence for involvement of tumor necrosis factor-α in apoptotic death of bone marrow cells in myelodysplastic syndromes. Am J Hematol. 1999; 60:36–47. PMID:
9883804.
7. Naganuma M, Sakuraba A, Hisamatsu T, et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. Inflamm Bowel Dis. 2008; 14:1259–1264. PMID:
18393375.
8. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89:2079–2088. PMID:
9058730.
9. Chen G, Zeng W, Miyazato A, et al. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood. 2004; 104:4210–4218. PMID:
15315976.
10. Lin YC, Liang TH, Chang HN, Lin JS, Lin HY. Behçet disease associated with myelodysplastic syndrome. J Clin Rheumatol. 2008; 14:169–174. PMID:
18525438.
11. Campioni D, Secchiero P, Corallini F, et al. Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol. 2005; 166:557–563. PMID:
15681838.
12. Lee RW, Dick AD. Treat early and embrace the evidence in favour of anti-TNF-α therapy for Behçet's uveitis. Br J Ophthalmol. 2010; 94:269–270. PMID:
20215370.
13. Duzgun N, Ayaslioglu E, Tutkak H, Aydintug OT. Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behçet's disease. Rheumatol Int. 2005; 25:1–5. PMID:
14600787.
14. Toyonaga T, Nakase H, Matsuura M, et al. Refractoriness of intestinal Behçet's disease with myelodysplastic syndrome involving trisomy 8 to medical therapies - our case experience and review of the literature. Digestion. 2013; 88:217–221. PMID:
24247154.
15. Iwata S, Saito K, Yamaoka K, et al. Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease. Mod Rheumatol. 2011; 21:184–191. PMID:
21052764.
16. Hisamatsu T, Ueno F, Matsumoto T, et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNFα monoclonal antibodies. J Gastroenterol. 2014; 49:156–162. PMID:
23955155.